SAN 61
Alternative Names: SAN-161; SAN-61Latest Information Update: 20 Mar 2013
Price :
$50 *
At a glance
- Originator Sanomune
- Class Antidementias; Recombinant proteins
- Mechanism of Action Amyloid beta-protein inhibitors; Amyloid inhibitors; Glycogen synthase kinase 3 inhibitors; Tau protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Neurological disorders
Most Recent Events
- 20 Mar 2013 No development reported - Preclinical for Alzheimer's disease in Canada (Intranasal)
- 20 Mar 2013 No development reported - Preclinical for Alzheimer's disease in Canada (PO)
- 20 Mar 2013 No development reported - Preclinical for Neurological disorders in Canada (Intranasal)